Paying users zone. Data is covered by 
.
Get to Biogen Inc. for $15.99, or
get to whole website for at least 3 months from $49.99.
Common-Size Statement of Financial Position, Liabilities and Stockholders' Equity
Difficulty: Beginner
Biogen Inc., Common-Size Consolidated Statement of Financial Position, Liabilities and Stockholders' Equity
| Dec 31, 2017 | Dec 31, 2016 | Dec 31, 2015 | Dec 31, 2014 | Dec 31, 2013 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current portion of notes payable and other financing arrangements | |
|
|
|
|
||||||
| Taxes payable | |
|
|
|
|
||||||
| Accounts payable | |
|
|
|
|
||||||
| Current portion of contingent consideration obligations | |
|
|
|
|
||||||
| Revenue-related reserves for discounts and allowances | |
|
|
|
|
||||||
| Employee compensation and benefits | |
|
|
|
|
||||||
| Royalties and licensing fees | |
|
|
|
|
||||||
| Collaboration expenses | |
|
|
|
|
||||||
| Construction in progress | |
|
|
|
|
||||||
| Accrued TECFIDERA litigation settlement charges | |
|
|
|
|
||||||
| Other | |
|
|
|
|
||||||
| Accrued expenses and other | |
|
|
|
|
||||||
| Current liabilities | |
|
|
|
|
||||||
| Notes payable and other financing arrangements, excluding current portion | |
|
|
|
|
||||||
| Deferred tax liability | |
|
|
|
|
||||||
| Other long-term liabilities | |
|
|
|
|
||||||
| Non-current liabilities | |
|
|
|
|
||||||
| Total liabilities | |
|
|
|
|
||||||
| Preferred stock, par value $0.001 per share | |
|
|
|
|
||||||
| Common stock, par value $0.0005 per share | |
|
|
|
|
||||||
| Additional paid-in capital | |
|
|
|
|
||||||
| Accumulated other comprehensive loss | |
|
|
|
|
||||||
| Retained earnings | |
|
|
|
|
||||||
| Treasury stock, at cost | |
|
|
|
|
||||||
| Total Biogen Inc. shareholders' equity | |
|
|
|
|
||||||
| Noncontrolling interests | |
|
|
|
|
||||||
| Total equity | |
|
|
|
|
||||||
| Total liabilities and equity | |
|
|
|
|
Based on: 10-K (filing date: 2018-02-01), 10-K (filing date: 2017-02-02), 10-K (filing date: 2016-02-03), 10-K (filing date: 2015-02-04), 10-K (filing date: 2014-02-06).
| Item | Description | The company |
|---|---|---|
| Current liabilities | Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer. | Biogen Inc.'s current liabilities as a percentage of total liabilities and equity increased from 2015 to 2016 but then slightly declined from 2016 to 2017. |
| Non-current liabilities | Amount of obligation due after one year or beyond the normal operating cycle, if longer. | Biogen Inc.'s non-current liabilities as a percentage of total liabilities and equity declined from 2015 to 2016 but then slightly increased from 2016 to 2017. |
| Total liabilities | Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future. | Biogen Inc.'s total liabilities as a percentage of total liabilities and equity declined from 2015 to 2016 and from 2016 to 2017. |
| Total Biogen Inc. shareholders' equity | Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity. | Biogen Inc.'s total Biogen Inc. shareholders' equity as a percentage of total liabilities and equity increased from 2015 to 2016 and from 2016 to 2017. |
